JAK2 (Exon 12) Mutation Analysis

The JAK2 exon 12 mutation test is a molecular genetic blood or bone-marrow assay that detects activating mutations in exon 12 of the JAK2 gene. It’s performed when polycythemia vera is suspected but the common JAK2 V617F mutation is negative. Finding exon 12 mutations supports diagnosis, helps distinguish myeloproliferative disorders, and informs prognosis and treatment decisions.

I can’t reliably recite JAK2 exon 12’s exact nucleotide sequence from memory. If you want the canonical sequence, I can fetch the exon 12 nucleotide (or translated amino‑acid) sequence from the JAK2 reference transcript (for example NM_004972.3), include coordinates and common mutation sites. Which format do you prefer: nucleotide or protein? I’ll then provide the exact sequence and mutation positions.

A positive JAK2 mutation test indicates a clonal blood disorder that drives overproduction of blood cells. It’s commonly associated with myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis. It isn’t a full diagnosis by itself; doctors will review blood counts, symptoms and may order bone marrow biopsy and targeted treatment to manage thrombosis risk and disease progression.

JAK2 gene mutation analysis is a molecular blood or bone marrow test that detects mutations (commonly V617F or exon 12) in the JAK2 tyrosine kinase gene. It helps diagnose myeloproliferative neoplasms—polycythaemia vera, essential thrombocythaemia and primary myelofibrosis—when unexplained high blood counts or splenomegaly occur. A positive result supports diagnosis, influences treatment choices and monitoring; negative results may prompt further testing.

A JAK2 mutation can be serious because it commonly causes myeloproliferative disorders (e.g., polycythemia vera, essential thrombocythemia, myelofibrosis). It raises risks of blood clots, progressive marrow dysfunction, and rarely transformation to acute leukemia. Severity varies—some people have mild disease managed with monitoring and treatment (phlebotomy, cytoreduction, JAK inhibitors). See a hematologist for evaluation and follow‑up.

The most common complication in essential thrombocythemia is thrombosis. Patients commonly develop arterial events (stroke, transient ischemic attack, myocardial infarction) and venous thromboses, with arterial events more frequent. Microvascular symptoms such as headache, erythromelalgia, and visual disturbance also occur. Thrombotic risk increases with age, prior thrombosis, and certain mutations, so prevention and risk stratification are key.